GPCR Allosteric Modulators: Mechanistic Advantages and Therapeutic Applications.
作者信息
Wold Eric A, Zhou Jia
机构信息
Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States.
出版信息
Curr Top Med Chem. 2018;18(23):2002-2006. doi: 10.2174/1568026619999190101151837.
Abstract
摘要
相似文献
1
GPCR Allosteric Modulators: Mechanistic Advantages and Therapeutic Applications.
Curr Top Med Chem. 2018;18(23):2002-2006. doi: 10.2174/1568026619999190101151837.
2
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.
Trends Pharmacol Sci. 2007 Aug;28(8):382-9. doi: 10.1016/j.tips.2007.06.004. Epub 2007 Jul 13.
3
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
J Med Chem. 2019 Jan 10;62(1):24-45. doi: 10.1021/acs.jmedchem.7b01844. Epub 2018 Feb 26.
4
Allosteric properties of G protein-coupled receptor oligomers.
Pharmacol Ther. 2007 Sep;115(3):410-8. doi: 10.1016/j.pharmthera.2007.06.004. Epub 2007 Jun 27.
5
Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs.
Curr Opin Drug Discov Devel. 2010 Sep;13(5):587-94.
6
[The pharmacological effect of allosteric regulation at GPCR heterodimer].
Sheng Li Ke Xue Jin Zhan. 2013 Apr;44(2):93-8.
7
Allosteric modulators of G-protein-coupled receptors.
Curr Opin Pharmacol. 2003 Oct;3(5):551-6. doi: 10.1016/s1471-4892(03)00107-3.
8
In search of negative allosteric modulators of biological targets.
Drug Discov Today. 2009 Jan;14(1-2):41-9. doi: 10.1016/j.drudis.2008.09.011. Epub 2008 Nov 13.
9
[Allosteric modulator of GPCRs and new drug targets].
Sheng Li Ke Xue Jin Zhan. 2012 Dec;43(6):459-62.
10
Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
Expert Opin Drug Discov. 2016 Dec;11(12):1223-1237. doi: 10.1080/17460441.2016.1245289. Epub 2016 Oct 21.
引用本文的文献
1
Gut-heart axis: cardiac remodeling and heart failure in the context of inflammatory bowel disease and dysbiosis.
Am J Physiol Gastrointest Liver Physiol. 2025 Jul 1;329(1):G122-G137. doi: 10.1152/ajpgi.00016.2025. Epub 2025 May 19.
2
Exploring Druggable Binding Sites on the Class A GPCRs Using the Residue Interaction Network and Site Identification by Ligand Competitive Saturation.
ACS Omega. 2024 Sep 13;9(38):40154-40171. doi: 10.1021/acsomega.4c06172. eCollection 2024 Sep 24.
3
Gut microbe-generated phenylacetylglutamine is an endogenous allosteric modulator of β2-adrenergic receptors.
Nat Commun. 2024 Aug 6;15(1):6696. doi: 10.1038/s41467-024-50855-3.
4
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.
Expert Opin Drug Discov. 2024 Sep;19(9):1023-1041. doi: 10.1080/17460441.2024.2385598. Epub 2024 Jul 30.
5
Smooth operator(s): dialing up and down neurotransmitter responses by G-protein regulators.
Trends Cell Biol. 2025 Apr;35(4):330-340. doi: 10.1016/j.tcb.2024.07.002. Epub 2024 Jul 24.
6
Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition.
Nat Rev Drug Discov. 2024 Aug;23(8):626-644. doi: 10.1038/s41573-024-00958-9. Epub 2024 Jun 18.
7
Recent Advances on Targeting Proteases for Antiviral Development.
Viruses. 2024 Feb 27;16(3):366. doi: 10.3390/v16030366.
8
How New Developments in Pharmacology Receptor Theory Are Changing (Our Understanding of) Hypertension Therapy.
Am J Hypertens. 2024 Mar 15;37(4):248-260. doi: 10.1093/ajh/hpad121.
9
Discovery of Novel Oleamide Analogues as Brain-Penetrant Positive Allosteric Serotonin 5-HT Receptor and Dual 5-HT/5-HT Receptor Modulators.
J Med Chem. 2023 Jul 27;66(14):9992-10009. doi: 10.1021/acs.jmedchem.3c00908. Epub 2023 Jul 18.
10
NanoB to monitor interactions of ligands with membrane proteins by combining nanobodies and NanoBRET.
Cell Rep Methods. 2023 Mar 13;3(3):100422. doi: 10.1016/j.crmeth.2023.100422. eCollection 2023 Mar 27.
本文引用的文献
1
Positive-allosteric modulation of the 5-HT receptor: implications for neuropsychopharmacology and neurotherapeutics.
Neuropsychopharmacology. 2019 Jan;44(1):230-231. doi: 10.1038/s41386-018-0190-x.
2
Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.
J Med Chem. 2019 Jan 10;62(1):88-127. doi: 10.1021/acs.jmedchem.8b00875. Epub 2018 Aug 28.
3
CCR5 adopts three homodimeric conformations that control cell surface delivery.
Sci Signal. 2018 May 8;11(529):eaal2869. doi: 10.1126/scisignal.aal2869.
4
Catalytic activation of β-arrestin by GPCRs.
Nature. 2018 May;557(7705):381-386. doi: 10.1038/s41586-018-0079-1. Epub 2018 May 2.
5
Molecular mechanism of GPCR-mediated arrestin activation.
Nature. 2018 May;557(7705):452-456. doi: 10.1038/s41586-018-0077-3. Epub 2018 May 2.
6
Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT Receptor.
J Med Chem. 2019 Jan 10;62(1):288-305. doi: 10.1021/acs.jmedchem.8b00401. Epub 2018 Apr 13.
7
Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs.
Nat Chem Biol. 2018 Feb;14(2):126-134. doi: 10.1038/nchembio.2527. Epub 2017 Dec 11.
8
Trends in GPCR drug discovery: new agents, targets and indications.
Nat Rev Drug Discov. 2017 Dec;16(12):829-842. doi: 10.1038/nrd.2017.178. Epub 2017 Oct 27.
9
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.
Neuron. 2017 May 3;94(3):431-446. doi: 10.1016/j.neuron.2017.03.016.
10
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.
Sci Signal. 2016 Nov 29;9(456):ra117. doi: 10.1126/scisignal.aai8441.
Zotero 插件